TwentyTwentyTweets
Tweets by 2020health-
Join 7,195 other subscribers
-
Recent Posts
Pages
Tag Archives: Drugs
Are pharmaceutical mega-mergers in the public interest?
The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development – R&D – with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played … Continue reading
Posted in Business, competition, Drugs, Innovation, International, Pharma, Policy, Research, Technology
Tagged 2020health, AstraZeneca, Beecham, Boots, competition, David Jack, Drugs, Glaxo, innovation, Keith Mansford, medicine, merger, Pfizer, pharmaceutical, R&D, Research, Sir David Jack, SmithKline, Smithkline Beecham, Tagamet, takeover
Leave a comment
Legal High Lies
It was terribly sad listening to the bother of a “legal high” victim on the radio this morning. The now banned N-Bomb LSD copycat drug had left his brother severely brain damaged and dependent on 24 hour care for the … Continue reading
Posted in Drugs
Tagged addiction, death, Drugs, Legal highs, psychoactive substances
Leave a comment
Guest Blogspot: Negotiations with the UK Government over pharmaceutical pricing have achieved a good result for patients, the NHS and the industry.
The UK Government and the pharmaceutical industry shared many objectives throughout the recent drug pricing negotiations. For example, there was always broad agreement that: The total future drug bill needed to be affordable in the context of other spending in … Continue reading
Posted in Andrew Lansley, Business, Cancer, Department of Health, Drugs, Innovation, Jeremy Hunt, NHS, Patients, Pharma, Research, Smoking ban
Tagged 2020health, Andrew Lansley, Department of Health, Drugs, government, innovation, Jeremy Hunt, National Health Service, NHS, NICE, parallel export, parallel imporrt, patient, Patient Access Scheme, Patients, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing, VBP
1 Comment
Bad for patients and bad for growth?
2020health today publish a review from a patient’s perspective of the Government’s plans to change the way medicines are priced. Featured in today’s FT (£) we point out that patients are usually blissfully unaware of pricing negotiations but the Government’s … Continue reading
Guest Blogspot: Waiting for Decisions on UK Pharmaceutical Pricing
Little has been heard over how confidential talks between the Government and the pharmaceutical industry are progressing towards the goal of having a new, voluntary UK drug pricing system in place in 2014. In the eyes of the pharmaceutical companies … Continue reading
Posted in Andrew Lansley, Business, Children, Commissioning, David Cameron, Department of Health, Drugs, Emerging technologies, equality, Health and Wellbeing, Innovation, Jeremy Hunt, Uncategorized, Wellbeing
Tagged 2020health, Andrew Lansley, Bowel Cancer UK, Cancer Research UK, Drugs, government, innovation, medicine, Multiple Sclerosis Society, pharmaceutical, R&D, value-based, value-based pricing
1 Comment
Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.
David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading
Posted in Business, competition, David Cameron, Department of Health, Drugs, Election, Jeremy Hunt, NHS, Patients, Pharma, Policy, Primary Care
Tagged 2020health, block-buster, competition, David Cameron, demand, Department of Health, drug pricing system, Drugs, elderly, GP, GPs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, parallel exports, parallel imports, patient, Patients, pharmaceutical, Philosophy and Economics, Politics, PPE, PPRS, pricing, quality of life, R&D, reference price, Research, value-based, value-based pricing, VBP
Leave a comment
Guest Blogspot: Do private patients in the UK help or harm the NHS?
Private medicine like private education and first-class travel can stir up feelings of resentment between the “haves” and “have-nots”. A short blog like this one has no possibility of uniting stereotypical politicians from the left and right wings of politics. … Continue reading
Posted in Business, Department of Health, Drugs, Elderly, GPs, Health Bill, Health Team, Healthcare, Hospitals, Inequality, mental health, NHS, Nursing, Patient choice, Patients, Pharma, Policy, Private, Research
Tagged 2020health, choice, Consultant, Cosmetic Surgery, Dental, Department of Health, Drugs, elderly, Gamma Knife, General practitioner, government, GP, GPs, health, Health Bill, Medical Insurance, medicine, mental health, National Health Service, NHS, outcomes, patient, Patients, pharmaceutical, Prescription Charge, Private Hospital, Private Medicine, Private Patient, Research
Leave a comment
Guest Blogspot: The Pharmaceutical Industry – Friend or Foe?
Recent months have seen publicity over examples of disgraceful behaviour by pharmaceutical companies. The question arises as to whether the failings have been rare and exceptional or whether they are indicative of generally low moral standards in the industry. Pharmaceutical … Continue reading
Posted in Alcohol, Business, Drugs, Finance, GPs, Information, NHS, Obesity, Research
Tagged 2020health, Abbott, alcohol, AstraZeneca, bribes, criminal, dishonest, Drugs, General practitioner, government, GP, GPs, GSK, innovation, Kuno Sommer, law breaking, life expectancy, Lilly, medicine, misleading, National Health Service, NHS, Obesity, patient, Patients, Paxil, Pfizer, pharmaceutical, practolol, pricing, R&D, Research, Responsibility in healthcare, Seroquel, thalidomide, tobacco, Wellbutrin, wrongdoing, Zhen Xiaoyu
Leave a comment
Sex, drugs and profligacy… just alcohol to go.
Laura Donnelly got a great scoop in the Sunday Telegraph at the weekend detailing the extraordinary amounts being spent by NHS Trusts on agency nursing. This not only demonstrates that certain hospitals’ management is out of control but also that … Continue reading
Guest Blogspot: A wrong decision on UK drug pricing could seriously undermine all the good work that HM Treasury and the Department for Business, Innovation and Skills have done to encourage the UK pharmaceutical industry.
The recent local elections highlight the political dangers ahead. The current UK coalition government has lost popularity through decisions that do not all relate to austerity measures. Shortly after the General Election Andrew Lansley’s plans to increase the say of … Continue reading
Posted in Andrew Lansley, Business, Department of Health, Drugs, Election, Global Health, Health Bill, NHS, Patient choice, Patients, Pharma, Policy, Research, Technology
Tagged 2020health, Andrew Lansley, AstraZeneca, Department of Health, Drugs, GlaxoSmithKline, GSK, health, Health Bill, innovation, medicine, National Health Service, NHS, NICE, patient, Patients, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
Leave a comment
2020health's Blog 
You must be logged in to post a comment.